Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 18, 2026.

Alzheimer's disease: synapses gone cold

Robert M Koffie, Bradley T Hyman, Tara L Spires-Jones

Molecular Neurodegeneration · 2011 · Review

doi:10.1186/1750-1326-6-63

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by insidious cognitive decline and memory dysfunction. Synapse loss is the best pathological correlate of cognitive decline in AD and mounting evidence suggests that AD is primarily a disease of synaptic dysfunction. Soluble oligomeric forms of amyloid beta (Aβ), the peptide that aggregates to form senile plaques in the brain of AD patients, have been shown to be toxic to neuronal synapses both in vitro and in vivo . Aβ oligomers inhibit long-term potentiation (LTP) and facilitate long-term depression (LTD), electrophysiological correlates of memory formation. Furthermore, oligomeric Aβ has also been shown to induce synapse loss and cognitive impairment in animals. The molecular underpinnings of these observations are now being elucidated, and may provide clear therapeutic targets for effectively treating the disease. Here, we review recent findings concerning AD pathogenesis with a particular focus on how Aβ impacts synapses.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Background

First described by the German neuropathologist Alois Alzheimer in 1906, Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by insidious cognitive decline and loss of memory function. Over 35 million people are afflicted with AD worldwide, 5.5 million of them in the United States alone, and these numbers are expected to quadruple by 2050. AD is the sixth leading cause of death in the United States, and remains one of the only causes of death that increased by as much as 66% over the last decade. No disease-modifying drug has been developed for treating AD, making it one of the most pressing public health problems in the world today. Tremendous progress has been made over the last few decades in understanding the underlying biology of the disease. Here we review pertinent research findings concerning AD pathogenesis with a particular focus on how neuronal synapses are impacted in disease progression. Understanding the molecular underpinnings of AD pathogenesis may aid in developing effective therapeutic approaches for combating it.

Neuropathology and Pathogenesis of Alzheimer's disease

AD is characterized pathologically by cortical atrophy, neuronal cell death, neuroinflammation, synapse loss, and the accumulation of two definitive pathological lesions: neurofibrillary tangles and senile plaques. Neurofibrillary tangles (NFTs) deposit within neurons and are composed of hyperphosphoryated tau protein whereas senile plaques occur in the extracellular space and are made up largely of the 38-43 amino acid peptide amyloid-beta (Aβ). Aβ is believed to be a key trigger of AD pathogenesis, one that is upstream of NFTs. It is formed by the sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretase, after which Aβ is released into the extracellular space. There, Aβ can assume a variety of conformational states ranging from monomers to soluble oligomers, protofibrils, and fibrils, which aggregate to form plaques.

Several lines of evidence support the hypothesis that alterations in amyloid processing can lead to AD. First, APP is located on chromosome 21, and Down syndrome patients who have trisomy of chromosome 21 invariably develop AD. Further, individuals with trisomy 21 with a chromosome 21q break such that APP diploidy occurs in the setting of trisomy 21 do not develop clinical or neuropathological AD. Conversely, a small cohort of patients who inherited an extra copy of APP due to microduplication of small portions of chromosome 21q containing the APP locus developed AD-like dementia with plaque deposition.

Second, most genetic mutations associated with rare familial early onset AD lead to increased production of Aβ or an increase in Aβ42-to-Aβ40 ratio, which increases the propensity for Aβ aggregation. Mutations leading to early onset familial AD have been found in the APP gene on chromosome 21q, in the presenilin 1 gene (PSEN 1) on chromosome 14q, and the presenilin 2 gene (PSEN 2, a homolog of PSEN 1) located on chromosome 1q. Presinilin forms the catalytic site of γ-secretase, which is one of the enzymes involved in the cleavage of APP to form Aβ All of these mutations influence Aβ metabolism and production.

Third, Aβ has been shown to be toxic to neurons in vitro and in vivo. Injecting synthetic or naturally secreted Aβ, at concentrations akin to those seen in the brains of AD patients, into the brains of rodents induces behavioral deficits and tau hyperphosphorylation.

Fourth, transgenic mouse models overexpressing human APP and/or PSEN genes with known familial early onset AD mutations develop amyloid plaque deposition and some of the morphological changes of AD (e.g. synapses loss). While most of these transgenic mice do not develop the typical neuronal cell loss observed in AD, they manifest age-dependent memory impairments and cognitive deficits.

Finally, immunization of AD transgenic mice with Aβ or anti-Aβ antibodies reduces amyloid plaque deposition, clears existing plaques, and ameliorates cognitive deficits in transgenic mice, indicating that removal of Aβ is beneficial to the brain.

Taken together, these findings suggest that Aβ is an essential element in the pathogenesis of AD. The mechanistic link between Aβ and neurodegeneration, however, remains elusive. Mounting evidence suggests that AD is primarily a disease of synaptic dysfunction and it is becoming clear that Aβ, particularly in oligomeric form, is toxic to synapses. There is therefore a growing interest in understanding how oligomeric Aβ induces synaptic dysfunction in AD.

Aβ-mediated synaptic dysfunction in Alzheimer's disease

AD brains are characterized by dramatic synapses loss in mesiotemporal regions. Significant synapse loss also occurs in patients with mild cognitive impairment, a harbinger for future AD. In fact, synapse loss is the best pathological correlate of cognitive dysfunction in AD, suggesting that synaptic changes are crucial for AD pathogenesis. Synapse loss is most prominent in the immediate vicinity of senile plaques, suggesting that plaques may be a reservoir of synaptotoxic molecules such as Aβ. Indeed, recent studies using multiphoton in vivo imaging revealed a halo of oligomeric Aβ around plaques in the brain of AD transgenic mice suggesting that oligomeric Aβ may exist in equilibrium with plaques in AD.

Aβ oligomerizes via an unknown mechanism, adopting several higher order conformations such as soluble dimers, trimers, dodecamers, higher order oligomers (also named Aβ-derived diffusible ligands (ADDL)), protofibrils, and fibrils. Most of these higher order Aβ structures have been found to be toxic to neurons. Synthetic Aβ oligomers or natural soluble oligomeric Aβ purified from the media of cultured cells expressing mutant human APP (hAPP) or extracted directly from the brains of AD patients have potent synaptic effects. Sodium dodecyl sulfate (SDS) stable Aβ oligomers, ADDLs and protofibrils have all been shown to induce synaptic dysfunction. Specifically, oligomeric Aβ inhibits the induction of long-term potentiation (LTP), an electrophysiological correlate of memory formation. Biophysical methods such as size exclusion chromatography (SEC) and mass spectroscopy have been used to show that Aβ dimers and trimers are most potent at inhibiting LTP. Inhibitors of Aβ oligomerization rescue impairment of LTP induced by Aβ containing media, suggesting that monomeric Aβ is not a potent inhibitor of LTP. Complementing its effects on LTP inhibition, oligomeric Aβ has also been shown to facilitate the induction of long-term depression (LTD) in hippocampal synapses. Impairments in LTP and facilitation of LTD culminate in synaptic depression and impairments in neuronal networks.

Molecular basis of oligomeric Aβ mediated synaptic depression

The molecular mechanisms underlying oligomeric Aβ-mediated synapse dysfunction is very complex. Oligomeric Aβ can induce calcium dyshomeostasis, trigger activation of caspases and calcineurin, and modulate the activity of synaptic excitatory receptors and receptor tyrosine kinases, instigating a cascade of molecular events that culminate in the inhibition of LTP, facilitation of LTD, and synapse loss (Figure 1).

Physiologically, LTP and LTD depend on calcium influx through N-methyl-D-aspartate (NMDA) receptors and/or activation of metabotropic glutamate receptors (mGluRs). Synapse potentiation or depression depends on the rate of influx of calcium as well as the level of cytosolic calcium. LTP occurs when rapid and high levels of calcium influx occur through NMDA receptors, whereas LTD is favored when low level calcium influx through NMDA receptors occurs. LTP requires the activation of NR2A containing NMDA receptors, whereas LTD requires activation of NR2B containing NMDA receptors. These different subclasses of NMDA receptors have distinct calcium influx kinetics and modulate distinct postsynaptic signaling pathways. LTP is associated with dendritic spine enlargement and increase in synapse density, whereas LTD leads to dendritic spine shrinkage and synapse collapse. Several protein kinases such as p38 mitogen-activated protein kinase (MAPK), calcium calmodoulin-dependent protein kinase II (CaMKII), glycogen synthase kinase 3-beta (GSK3β), and ephrin receptor B2 (EphB2) have all been shown to modulate LTP induction in the brain. Phosphatases and proteases such as calcineurin (protein phosphatase 2B [PP2B]) and caspases play key intracellular roles in the induction of LTD. Transcription factors such as the cyclic AMP response element binding protein (CREB) are crucial for the induction of continuous LTP, by increasing the expression of several genes including those encoding brain derive neurotrophic factor (BDNF) and nitric oxide synthase.

Oligomeric Aβ has been shown to inhibit LTP and enhance LTD by modulating the activity of all of the above molecular pathways. Oligomeric Aβ-induced loss of excitatory synapses in the hippocampus requires functional NMDA receptors. Several studies have shown that oligomeric Aβ induces partial blockade of NMDA receptor currents, which leads to reduction of calcium influx into spines promoting LTD over LTP. Aβ binds to 7α-nicotinic acetylcholine receptors (nAchR), triggering a series of events that leads to internalization of NMDA receptors via a mechanism requiring calcineurin activation. Reduced calcium influx through NMDA receptors induced by Aβ limits CAMKII function, LTP, and spine enlargement. In fact, oligomeric Aβ-mediated LTP impairment is believed to involve a decrease in the activation of MAPK, CaMKII and Akt/protein kinase B, but not protein kinases A and C. Aβ has also been shown to induce synaptic depression by activating mGluRs, which triggers a series of downstream molecular events involving MAPK and calcineurin, ultimately promoting internalization of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and synapse collapse. In vivo studies suggest that Aβ indirectly modulates calcineurin activation by causing calcium dysregulation. Calcineurin activation promotes the induction of LTD by decreasing surface expression of NMDA receptors and increasing internalization of AMPA receptors via dynamin-mediated endocytosis. Indeed, Aβ-mediated internalization of AMPA and NMDA receptors, loss of dendritic spines, and cognitive decline can all be rescued by inhibiting calcineurin activation, indicating that calcineurin plays a crucial role in Aβ-dependent modulation of synaptic plasticity. Further, oligomeric Aβ activation of calcineurin has been shown to induce dendritic simplification, spine loss, and neuritic dystrophies at least in part by activating NFAT (nuclear factor of activated T-cells) pathways both in vitro and in vivo. Oligomeric Aβ has also been shown to activate other synaptic phosphatases such as STEP (striatal-enriched tyrosine phosphatase), which function to dephosphorylate NR2B subunits of NMDA receptors and promote their endocytosis, thereby inducing synaptic depression.

Oligomeric Aβ can also directly interact with synaptic surface receptor tyrosine kinases that play key roles in LTP and LTD modulation. For instance, it has been shown that oligomeric Aβ binds to the fibronectin domain of EphB2, a receptor tyrosine kinase known to modulate NMDA receptor trafficking and downstream transcription factors such as Fos, which plays a critical role in the induction of LTP. Oligomeric Aβ binding to EphB2 promotes its degradation in the proteasome, impairing the induction of LTP. Indeed, EphB2 is depleted in the brains of transgenic hAPP mice and AD patients, and replacement of EphB2 reverses cognitive impairment in hAPP mice.

Other studies have shown that Aβ facilitates hippocampal LTD via a mechanism that depends on both NMDAR and mGluR activity. Exogenous extracellular glutamate scavengers reverse oligomeric Aβ mediated facilitation of LTD, whereas inhibitors of glutamate reuptake mimic oligomeric Aβ-mediated LTD facilitation, suggesting that the effects of oligomeric Aβ-mediated LTD facilitation may occur as a result of impaired glutamate reuptake at the synapse, leading to post-synaptic NMDA receptor desensitization. Metabotropic glutamate receptor activity, GSK-3β signaling, and protein phosphatase 2B activity are all necessary for oligomeric-Aβ mediated LTD enhancement.

Caspase-3 activity has also been found to be crucial for oligomeric Aβ-mediated facilitation of LTD. Soluble Aβ induces caspase-3 activation at a low level that is not sufficient to induce apoptosis. Mitochondria-dependent caspase-3 activation is necessary for physiologic LTD via a mechanism involving Akt proteolysis. Soluble Aβ activates caspase-3, which leads to LTD via a mechanism involving activation of different protein phosphatases that dephosphorylate AMPA receptors and promote their endocytosis from synaptic surfaces, suggesting that prevention of caspase-3 activation may be a viable therapeutic approach for treating AD. Acute inhibition of caspase-3 activity is beneficial, but unfortunately, chronic inhibition of caspase-3 activation beyond the baseline did not reverse cognitive decline in hAPP mice, but instead exacerbated cognitive impairment, possibly due to a requirement for caspase-3 activity in normal synaptic function. Aβ also influences CREB activation, which is crucial for the maintenance of LTP, insofar as CREB regulates the expression of genes necessary for LTP. One study showed that Aβ decreases the activity of CREB and thus reduces expression of genes encoding proteins that are essential for LTP. Another study found that excessive activation of extrasynaptic NR2B-containing NMDA receptors, which leads to downregulation of CREB underlies oligomeric Aβ-mediated LTP inhibition.

Oligomeric Aβ causes synapse shrinkage in Alzheimer's disease

The acute effects of Aβ on synaptic physiology appear to translate into structural changes in synaptic morphology because enhanced LTD leads to dendritic spine shrinkage whereas inhibition of LTP limits spine enlargement. Exposure of cultured neurons or rat hippocampal slices to oligomeric Aβ induces dendritic spine shrinkage and collapse, a phenomenon that can be reversed by treatment with Aβ antibodies. APP transgenic mice have significant synapse loss and neutralization of oligomeric Aβ with anti-Aβ antibodies leads to reversal of synapse collapse. Furthermore, increased concentration of Aβ may reduce glutamatergic transmission and leads to synapse loss in hAPP transgenic mice even before plaque formation. Oligomeric Aβ-mediated inhibition of LTP and enhancement of LTD lead to dendritic spine loss as a result of F-actin remodeling. LTD accompanied by shrinkage of dendritic spines occurs via a mechanism involving cofilin-mediated depolymerization of actin. Specifically, Aβ indirectly stimulates cofilin binding to actin and induction of actin depolymerization in neuronal cytoskeleton. Binding of cofilin to actin is promoted by dephosphorylation at Ser3 by phosphatase Slingshot, and inhibited by phosphorylation by LIM kinase 1, a process that is modulated by oligomeric Aβ. Indeed, in addition to dendritic spine protein loss, increased amounts of dephosphorylated cofilin have been found in the brain of AD patients.

Oligomeric Aβ induces cognitive impairments

The electrochemical and structural effects of oligomeric Aβ on synapses described above may lead to potent behavioral and cognitive deficits in animals. Intra-cerebral injection of synthetic or naturally secreted oligomeric Aβ impairs complex behavior including memory and cognitive function in animals. APP transgenic mice with increased soluble Aβ in the brain display dramatic cognitive impairments even before the onset of plaque deposition. Neutralization of soluble oligomeric Aβ with anti-Aβ antibodies reverses behavioral deficits seen in different AD transgenic mice, suggesting that behavioral deficits in AD transgenic mice are caused by soluble Aβ. Inhibition of oligomeric Aβ formation decreases both histopathological and behavioral AD phenotypes in APP transgenic mice, implicating higher order Aβ structures such as soluble oligomeric Aβ, but not Aβ monomers, in AD pathogenesis. Levels of soluble oligomeric Aβ, but not senile plaques, in the brain correlates with severity of memory loss in human AD patients, however, the precise contribution of different Aβ species to cognitive decline is not clear.

While it is now well-established that increased oligomeric Aβ levels in the brain leads to synaptic dysfunction, it should be noted that at physiologic levels, Aβ might play a normal role in modulating synaptic activity, which likely becomes deranged in the setting of excess Aβ production or accumulation, leading ultimately to the clinical manifestation of cognitive impairment. Indeed, there is a small but growing body of evidence suggesting that Aβ at low concentrations actually promotes LTP and normal synaptic function. Thus, therapeutic approaches aimed at improving cognition by counteracting the toxic effects of Aβ will have to be tailored to target only the toxic function of oligomeric Aβ. Nonspecific total inhibition of Aβ may lead to negative effects on synaptic function and cognition.

Seeing Aβ in action at synapses

Collectively, all of the above evidence suggests that soluble oligomeric Aβ is a potent mediator of cognitive impairment in AD. Oligomeric Aβ inhibits the induction of LTP, lowers the threshold for inducing LTD, and causes synapse collapse, which may ultimately lead to cognitive decline resulting from disrupted neuronal network connectivity. For several years, limitations in the resolution of conventional microscopy techniques made it difficult to ascertain whether oligomeric Aβ directly associates with neuronal synapses and plays a role in their shrinkage and collapse in vivo. Recent advances in high-resolution microscopy techniques have made it possible to address these questions. For example development of array tomography, an ultra-high resolution fluorescence imaging technique that allow direct simultaneous visualization of several thousand small structures such as synapses and peptides in tissue has allowed determination of whether oligomeric Aβ plays a direct role in synapse loss in AD. Using array tomography and a conformation specific antibody (NAB61), we demonstrated that oligomeric Aβ in the brain of APP/PS1 transgenic mice directly colocalizes with a subset of synapses and is associated with their shrinkage and collapse (Figure 2), suggesting that the in vitro effects of Aβ oligomers observed using cell based assays likely also occur in vivo, supporting the notion that oligomeric Aβ adversely impacts synapses. High-resolution techniques such as array tomography could be extended to study the effects of oligomeric Aβ on synapses in the brain of AD patients. Furthermore, it will be important to determine whether Aβ oligomers are targeted to synapses by specific carrier proteins or whether they are produced locally at synapses. A number of studies have suggested that production of Aβ (at least in monomeric form) is regulated by activity and Aβ appears to play a negative feedback function on synaptic activity. Mechanistically, synaptic activity-dependent production of Aβ requires clathrin-mediated endocytosis of APP, which is then cleaved by β- and γ-secretase in late endosomes at synapses to form Aβ. Nonetheless, it is also possible that Aβ binding proteins like apolipoprotein E, which also play a role at the synapse, may stabilize Aβ oligomers in the extracellular space and deliver them to synaptic sites.

It is presently unclear whether Aβ oligomers interact directly with specific high affinity receptors at the synapse to induce synapse dysfunction. A number of recent studies have reported high affinity binding of oligomeric Aβ to cellular prion protein (PrPC), which was necessary for Aβ to mediate acute synaptic depression, synapse loss, and cognitive impairment in vivo. Subsequent studies, however, could not reproduce these findings. This is likely because of differences in experimental paradigms used in the subsequent studies. Single particle tracking of Aβ oligomers labeled with quantum dots exposed to hippocampal neurons in culture have nonetheless demonstrated that the diffusion of Aβ oligomers is dramatically limited upon binding to synaptic sites, suggesting that high affinity oligomeric Aβ receptors may be present at synapses. Identifying these high affinity receptors could aid in designing drugs capable of blocking the deleterious effects of oligomeric Aβ on neuronal synapses.

Concluding remarks

Based on the evidence discussed here, we postulate that AD begins as a disease of synaptic dysfunction and synapse loss then progresses to include widespread neuronal loss and neuronal network failure. Findings from recent experiments continue to provide insight into the complicated molecular underpinnings of synapse dysfunction in AD with mounting evidence pointing to soluble oligomeric Aβ as a key player in the induction of synaptic failure. Oligomeric Aβ activates a variety of molecular cascades that culminate in synapse dysfunction, shrinkage, collapse and loss (Figure 1). These pathological Aβ-triggered molecular events, however, may become independent of Aβ as the disease progresses, with downstream tau effects causing overt neuronal loss, exacerbating the loss of connectivity between neurons. If this is correct, at least two main therapeutic approaches could be taken to combat the disease effectively: 1) early interventions that prevent the initiation of Aβ-triggered pathological events; or 2) inhibition of specific downstream pathways activated by Aβ. The failure of previous therapeutic approaches aimed at removing toxic Aβ species from the brain (e.g. active immunization with Aβ peptide) in clinical trials may be because they were given to the wrong cohort of patients (i.e. patients with advanced AD, whose Aβ-triggered neuronal events may have become independent of Aβ). Perhaps, a more effective approach will be to initiate such anti-Aβ therapeutic regimens at very early stages of the disease. For this approach to be successful, highly sensitive and specific biomarkers for diagnosing AD need to be developed to identify AD patients at the very early stages of the disease. For patients who have progressed into symptomatic AD, it will likely be necessary to target pathways downstream of Aβ, including tau hyperphosphorylation and accumulation in the soma, which are linked to neuronal death. In conclusion, Aβ-mediated synaptic dysfunction appears to be an important driving factor in AD pathogenesis and understanding the molecular underpinnings may provide effective therapeutic targets for combating the disease.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

RMK designed the layout and content of the review; RMK collected illustrative data, RMK, BTH, and TLS-J wrote the text; all authors read and approved the final manuscript.

References 142

  1. 1.

    Alzheimer A Ubereine eigenartige Erkrankung der HirnrindeAllgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin1907 64146148

    Not in our library

  2. 2.

    Goedert M Spillantini MG A century of Alzheimer's diseaseScience2006 3145800777781

    Not in our library10.1126/science.1132814

  3. 3.

    Hebert LE Scherr PA Bienias JL Bennett DA Evans DA Alzheimer disease in the US population: prevalence estimates using the 2000 censusArch Neurol2003 60811191122

    Not in our library10.1001/archneur.60.8.1119

  4. 4.

    Alzheimer's A Thies W Bleiler L 2011 Alzheimer's disease facts and figuresAlzheimers Dement2011 72208244

    Not in our library10.1016/j.jalz.2011.02.004

  5. 5.

    Holtzman DM Morris JC Goate AM Alzheimer's disease: the challenge of the second centurySci Transl Med2011 37777sr71

    Not in our library10.1126/scitranslmed.3002369

  6. 6.

    Hardy J Selkoe DJ The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeuticsScience2002 2975580353356

    Not in our library10.1126/science.1072994

  7. 7.

    Kayed R Head E Thompson JL McIntire TM Milton SC Cotman CW Glabe CG Common structure of soluble amyloid oligomers implies common mechanism of pathogenesisScience2003 3005618486489

    Not in our library10.1126/science.1079469

  8. 8.

    Lansbury PT Jr Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and diseaseProc Natl Acad Sci USA1999 96733423344

    Not in our library10.1073/pnas.96.7.3342

  9. 9.

    Lansbury PT Jr In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical informationBiochemistry1992 313068656870

    Not in our library10.1021/bi00145a001

  10. 10.

    Tanzi RE Bertram L Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspectiveCell2005 1204545555

    Not in our library10.1016/j.cell.2005.02.008

  11. 11.

    Prasher VP Farrer MJ Kessling AM Fisher EM West RJ Barber PC Butler AC Molecular mapping of Alzheimer-type dementia in Down's syndromeAnn Neurol1998 433380383

    Not in our library10.1002/ana.410430316

  12. 12.

    Rovelet-Lecrux A Hannequin D Raux G Le Meur N Laquerriere A Vital A Dumanchin C Feuillette S Brice A Vercelletto M APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathyNat Genet2006 3812426

    Not in our library10.1038/ng1718

  13. 13.

    Bertram L Lill CM Tanzi RE The genetics of Alzheimer disease: back to the futureNeuron2010 682270281

    Not in our library10.1016/j.neuron.2010.10.013

  14. 14.

    Bertram L Tanzi RE Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analysesNat Rev Neurosci2008 910768778

    Not in our library10.1038/nrn2494

  15. 15.

    Osenkowski P Ye W Wang R Wolfe MS Selkoe DJ Direct and potent regulation of gamma-secretase by its lipid microenvironmentJ Biol Chem2008 283332252922540

    Not in our library10.1074/jbc.m801925200

  16. 16.

    Selkoe DJ Wolfe MS In search of gamma-secretase: presenilin at the cutting edgeProc Natl Acad Sci USA2000 971156905692

    Not in our library10.1073/pnas.97.11.5690

  17. 17.

    Wolfe MS Xia W Ostaszewski BL Diehl TS Kimberly WT Selkoe DJ Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activityNature1999 3986727513517

    Not in our library10.1038/19077

  18. 18.

    Murakami K Irie K Morimoto A Ohigashi H Shindo M Nagao M Shimizu T Shirasawa T Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's diseaseJ Biol Chem2003 278464617946187

    Not in our library10.1074/jbc.m301874200

  19. 19.

    Tsubuki S Takaki Y Saido TC Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradationLancet2003 361937319571958

    Not in our library10.1016/s0140-6736(03)13555-6

  20. 20.

    Games D Adams D Alessandrini R Barbour R Borthelette P Blackwell C Carr T Clemens J Donaldson T Gillespie F Alzheimer-type neuropathology in transgenic mice overexpressing V717F [beta]-amyloid precursor proteinNature1995 3736514523527

    Not in our library10.1038/373523a0

  21. 21.

    Mucke L Masliah E Yu GQ Mallory M Rockenstein EM Tatsuno G Hu K Kholodenko D Johnson-Wood K McConlogue L High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formationJ Neurosci2000 201140504058

    Not in our library10.1523/jneurosci.20-11-04050.2000

  22. 22.

    Lesne S Koh MT Kotilinek L Kayed R Glabe CG Yang A Gallagher M Ashe KH A specific amyloid-beta protein assembly in the brain impairs memoryNature2006 4407082352357

    Not in our library10.1038/nature04533

  23. 23.

    Oddo S Billings L Kesslak JP Cribbs DH LaFerla FM Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasomeNeuron2004 433321332

    Not in our library10.1016/j.neuron.2004.07.003

  24. 24.

    Lemere CA Masliah E Can Alzheimer disease be prevented by amyloid-beta immunotherapy?Nat Rev Neurol2010 62108119

    Not in our library10.1038/nrneurol.2009.219

  25. 25.

    Selkoe DJ Alzheimer's disease is a synaptic failureScience2002 2985594789791

    Not in our library10.1126/science.1074069

  26. 26.

    Masliah E Mallory M Alford M DeTeresa R Hansen LA McKeel DW Morris JC Altered expression of synaptic proteins occurs early during progression of Alzheimer's diseaseNeurology2001 561127129

    Not in our library10.1212/wnl.56.1.127

  27. 27.

    DeKosky ST Scheff SW Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severityAnn Neurol1990 275457464

    Not in our library10.1002/ana.410270502

  28. 28.

    Terry RD Masliah E Salmon DP Butters N DeTeresa R Hill R Hansen LA Katzman R Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairmentAnn Neurol1991 304572580

    Not in our library10.1002/ana.410300410

  29. 29.

    Davies CA Mann DM Sumpter PQ Yates PO A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's diseaseJ Neurol Sci1987 782151164

    Not in our library10.1016/0022-510x(87)90057-8

  30. 30.

    Scheff SW Price DA Schmitt FA DeKosky ST Mufson EJ Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairmentNeurology2007 681815011508

    Not in our library10.1212/01.wnl.0000260698.46517.8f

  31. 31.

    DeKosky ST Scheff SW Styren SD Structural correlates of cognition in dementia: quantification and assessment of synapse changeNeurodegeneration1996 54417421

    Not in our library10.1006/neur.1996.0056

  32. 32.

    Coleman PD Yao PJ Synaptic slaughter in Alzheimer's diseaseNeurobiol Aging2003 24810231027

    Not in our library10.1016/j.neurobiolaging.2003.09.001

  33. 33.

    Lanz TA Carter DB Merchant KM Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotypeNeurobiol Dis2003 133246253

    Not in our library10.1016/s0969-9961(03)00079-2

  34. 34.

    Moolman DL Vitolo OV Vonsattel JP Shelanski ML Dendrite and dendritic spine alterations in Alzheimer modelsJ Neurocytol2004 333377387

    Not in our library10.1023/b:neur.0000044197.83514.64

  35. 35.

    Tsai J Grutzendler J Duff K Gan WB Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branchesNat Neurosci2004 71111811183

    Not in our library10.1038/nn1335

  36. 36.

    Spires TL Hannan AJ Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in WarsawFEBS J2005 2721023472361

    Not in our library10.1111/j.1742-4658.2005.04677.x

  37. 37.

    Koffie RM Meyer-Luehmann M Hashimoto T Adams KW Mielke ML Garcia-Alloza M Micheva KD Smith SJ Kim ML Lee VM Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaquesProc Natl Acad Sci USA2009 1061040124017

    Not in our library10.1073/pnas.0811698106

  38. 38.

    Hartley DM Walsh DM Ye CP Diehl T Vasquez S Vassilev PM Teplow DB Selkoe DJ Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neuronsJ Neurosci1999 192088768884

    Not in our library10.1523/jneurosci.19-20-08876.1999

  39. 39.

    Walsh DM Hartley DM Kusumoto Y Fezoui Y Condron MM Lomakin A Benedek GB Selkoe DJ Teplow DB Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediatesJ Biol Chem1999 274362594525952

    Not in our library10.1074/jbc.274.36.25945

  40. 40.

    Harper JD Wong SS Lieber CM Lansbury PT Observation of metastable Abeta amyloid protofibrils by atomic force microscopyChem Biol1997 42119125

    Not in our library10.1016/s1074-5521(97)90255-6

  41. 41.

    Lambert MP Barlow AK Chromy BA Edwards C Freed R Liosatos M Morgan TE Rozovsky I Trommer B Viola KL Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxinsProc Natl Acad Sci USA1998 951164486453

    Not in our library10.1073/pnas.95.11.6448

  42. 42.

    Lashuel HA Hartley D Petre BM Walz T Lansbury PT Jr Neurodegenerative disease: amyloid pores from pathogenic mutationsNature2002 4186895291

    Not in our library10.1038/418291a

  43. 43.

    Walsh DM Tseng BP Rydel RE Podlisny MB Selkoe DJ The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brainBiochemistry2000 39351083110839

    Not in our library10.1021/bi001048s

  44. 44.

    Walsh DM Klyubin I Fadeeva JV Cullen WK Anwyl R Wolfe MS Rowan MJ Selkoe DJ Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivoNature2002 4166880535539

    Not in our library10.1038/416535a

  45. 45.

    Lesné S Koh MT Kotilinek L Kayed R Glabe CG Yang A Gallagher M Ashe KH A specific amyloid-[beta] protein assembly in the brain impairs memory2006 4407082352357

    Not in our library10.1038/nature04533

  46. 46.

    Enya M Morishima-Kawashima M Yoshimura M Shinkai Y Kusui K Khan K Games D Schenk D Sugihara S Yamaguchi H Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during agingAm J Pathol1999 1541271279

    Not in our library10.1016/s0002-9440(10)65273-x

  47. 47.

    Funato H Enya M Yoshimura M Morishima-Kawashima M Ihara Y Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formationAm J Pathol1999 15512328

    Not in our library10.1016/s0002-9440(10)65094-8

  48. 48.

    Roher AE Chaney MO Kuo YM Webster SD Stine WB Haverkamp LJ Woods AS Cotter RJ Tuohy JM Krafft GA Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's diseaseJ Biol Chem1996 271342063120635

    Not in our library10.1074/jbc.271.34.20631

  49. 49.

    Wang HW Pasternak JF Kuo H Ristic H Lambert MP Chromy B Viola KL Klein WL Stine WB Krafft GA Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrusBrain Res2002 9242133140

    Not in our library10.1016/s0006-8993(01)03058-x

  50. 50.

    Townsend M Shankar GM Mehta T Walsh DM Selkoe DJ Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimersJ Physiol2006 572Pt 2477492

    Not in our library10.1113/jphysiol.2005.103754

  51. 51.

    Shankar GM Bloodgood BL Townsend M Walsh DM Selkoe DJ Sabatini BL Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathwayJ Neurosci2007 271128662875

    Not in our library10.1523/jneurosci.4970-06.2007

  52. 52.

    Shankar GM Li S Mehta TH Garcia-Munoz A Shepardson NE Smith I Brett FM Farrell MA Rowan MJ Lemere CA Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNat Med2008 148837842

    Not in our library10.1038/nm1782

  53. 53.

    Townsend M Mehta T Selkoe DJ Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathwayJ Biol Chem2007 282463330533312

    Not in our library10.1074/jbc.m610390200

  54. 54.

    Walsh DM Townsend M Podlisny MB Shankar GM Fadeeva JV El Agnaf O Hartley DM Selkoe DJ Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiationJ Neurosci2005 251024552462

    Not in our library10.1523/jneurosci.4391-04.2005

  55. 55.

    Li S Hong S Shepardson NE Walsh DM Shankar GM Selkoe D Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptakeNeuron2009 626788801

    Not in our library10.1016/j.neuron.2009.05.012

  56. 56.

    Kim JH Anwyl R Suh YH Djamgoz MB Rowan MJ Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivoJ Neurosci2001 21413271333

    Not in our library10.1523/jneurosci.21-04-01327.2001

  57. 57.

    Palop JJ Mucke L Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networksNat Neurosci2010 137812818

    Not in our library10.1038/nn.2583

  58. 58.

    Kemp N Bashir ZI Long-term depression: a cascade of induction and expression mechanismsProg Neurobiol2001 654339365

    Not in our library10.1016/s0301-0082(01)00013-2

  59. 59.

    Wu J Rowan MJ Anwyl R Long-term potentiation is mediated by multiple kinase cascades involving CaMKII or either PKA or p42/44 MAPK in the adult rat dentate gyrus in vitroJ Neurophysiol2006 95635193527

    Not in our library10.1152/jn.01235.2005

  60. 60.

    Harney SC Rowan M Anwyl R Long-term depression of NMDA receptor-mediated synaptic transmission is dependent on activation of metabotropic glutamate receptors and is altered to long-term potentiation by low intracellular calcium bufferingJ Neurosci2006 26411281132

    Not in our library10.1523/jneurosci.2753-05.2006

  61. 61.

    Anwyl R Induction and expression mechanisms of postsynaptic NMDA receptor-independent homosynaptic long-term depressionProg Neurobiol2006 7811737

    Not in our library10.1016/j.pneurobio.2005.12.001

  62. 62.

    Citri A Malenka RC Synaptic plasticity: multiple forms, functions, and mechanismsNeuropsychopharmacology2008 3311841

    Not in our library10.1038/sj.npp.1301559

  63. 63.

    Kullmann DM Lamsa KP Long-term synaptic plasticity in hippocampal interneuronsNat Rev Neurosci2007 89687699

    Not in our library10.1038/nrn2207

  64. 64.

    Liu L Wong TP Pozza MF Lingenhoehl K Wang Y Sheng M Auberson YP Wang YT Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticityScience2004 304567310211024

    Not in our library10.1126/science.1096615

  65. 65.

    Sheng M Cummings J Roldan LA Jan YN Jan LY Changing subunit composition of heteromeric NMDA receptors during development of rat cortexNature1994 3686467144147

    Not in our library10.1038/368144a0

  66. 66.

    Chen N Luo T Raymond LA Subtype-dependence of NMDA receptor channel open probabilityJ Neurosci1999 191668446854

    Not in our library10.1523/jneurosci.19-16-06844.1999

  67. 67.

    Sprengel R Suchanek B Amico C Brusa R Burnashev N Rozov A Hvalby O Jensen V Paulsen O Andersen P Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivoCell1998 922279289

    Not in our library10.1016/s0092-8674(00)80921-6

  68. 68.

    Sheng M Pak DT Ligand-gated ion channel interactions with cytoskeletal and signaling proteinsAnnu Rev Physiol2000 62755778

    Not in our library10.1146/annurev.physiol.62.1.755

  69. 69.

    Matsuzaki M Honkura N Ellis-Davies GC Kasai H Structural basis of long-term potentiation in single dendritic spinesNature2004 4296993761766

    Not in our library10.1038/nature02617

  70. 70.

    Nagerl UV Eberhorn N Cambridge SB Bonhoeffer T Bidirectional activity-dependent morphological plasticity in hippocampal neuronsNeuron2004 445759767

    Not in our library10.1016/j.neuron.2004.11.016

  71. 71.

    Zhou Q Homma KJ Poo MM Shrinkage of dendritic spines associated with long-term depression of hippocampal synapsesNeuron2004 445749757

    Not in our library10.1016/j.neuron.2004.11.011

  72. 72.

    Bastrikova N Gardner GA Reece JM Jeromin A Dudek SM Synapse elimination accompanies functional plasticity in hippocampal neuronsProc Natl Acad Sci USA2008 105831233127

    Not in our library10.1073/pnas.0800027105

  73. 73.

    Wang Q Walsh DM Rowan MJ Selkoe DJ Anwyl R Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5J Neurosci2004 241333703378

    Not in our library10.1523/jneurosci.1633-03.2004

  74. 74.

    Tackenberg C Brandt R Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tauJ Neurosci2009 29461443914450

    Not in our library10.1523/jneurosci.3590-09.2009

  75. 75.

    Li Z Jo J Jia JM Lo SC Whitcomb DJ Jiao S Cho K Sheng M Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalizationCell2010 1415859871

    Not in our library10.1016/j.cell.2010.03.053

  76. 76.

    Mayr BM Canettieri G Montminy MR Distinct effects of cAMP and mitogenic signals on CREB-binding protein recruitment impart specificity to target gene activation via CREBProc Natl Acad Sci USA2001 98191093610941

    Not in our library10.1073/pnas.191152098

  77. 77.

    Mayr B Montminy M Transcriptional regulation by the phosphorylation-dependent factor CREBNat Rev Mol Cell Biol2001 28599609

    Not in our library10.1038/35085068

  78. 78.

    Cummings BJ Pike CJ Shankle R Cotman CW Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's diseaseNeurobiol Aging1996 176921933

    Not in our library10.1016/s0197-4580(96)00170-4

  79. 79.

    Mulkey RM Endo S Shenolikar S Malenka RC Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depressionNature1994 3696480486488

    Not in our library10.1038/369486a0

  80. 80.

    Wang HY Lee DH D'Andrea MR Peterson PA Shank RP Reitz AB beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathologyJ Biol Chem2000 275856265632

    Not in our library10.1074/jbc.275.8.5626

  81. 81.

    Snyder EM Nong Y Almeida CG Paul S Moran T Choi EY Nairn AC Salter MW Lombroso PJ Gouras GK Regulation of NMDA receptor trafficking by amyloid-betaNat Neurosci2005 8810511058

    Not in our library10.1038/nn1503

  82. 82.

    Nicoll RA Malenka RC Expression mechanisms underlying NMDA receptor-dependent long-term potentiationAnn N Y Acad Sci1999 868515525

    Not in our library10.1111/j.1749-6632.1999.tb11320.x

  83. 83.

    Jo J Whitcomb DJ Olsen KM Kerrigan TL Lo SC Bru-Mercier G Dickinson B Scullion S Sheng M Collingridge G Abeta(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3betaNat Neurosci2011 145545547

    Not in our library10.1038/nn.2785

  84. 84.

    D'Amelio M Cavallucci V Middei S Marchetti C Pacioni S Ferri A Diamantini A De Zio D Carrara P Battistini L Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's diseaseNat Neurosci2011 1416976

    Not in our library10.1038/nn.2709

  85. 85.

    Hsieh H Boehm J Sato C Iwatsubo T Tomita T Sisodia S Malinow R AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine lossNeuron2006 525831843

    Not in our library10.1016/j.neuron.2006.10.035

  86. 86.

    Abdul HM Sama MA Furman JL Mathis DM Beckett TL Weidner AM Patel ES Baig I Murphy MP LeVine H Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signalingJ Neurosci2009 29411295712969

    Not in our library10.1523/jneurosci.1064-09.2009

  87. 87.

    Kuchibhotla KV Goldman ST Lattarulo CR Wu HY Hyman BT Bacskai BJ Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networksNeuron2008 592214225

    Not in our library10.1016/j.neuron.2008.06.008

  88. 88.

    Wen Z Guirland C Ming GL Zheng JQ A CaMKII/calcineurin switch controls the direction of Ca(2+)-dependent growth cone guidanceNeuron2004 436835846

    Not in our library10.1016/j.neuron.2004.08.037

  89. 89.

    Slepnev VI Ochoa GC Butler MH Grabs D De Camilli P Role of phosphorylation in regulation of the assembly of endocytic coat complexesScience1998 2815378821824

    Not in our library10.1126/science.281.5378.821

  90. 90.

    Dineley KT Hogan D Zhang WR Taglialatela G Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic miceNeurobiol Learn Mem2007 882217224

    Not in our library10.1016/j.nlm.2007.03.010

  91. 91.

    Wu HY Hudry E Hashimoto T Kuchibhotla K Rozkalne A Fan Z Spires-Jones T Xie H Arbel-Ornath M Grosskreutz CL Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activationJ Neurosci2010 30726362649

    Not in our library10.1523/jneurosci.4456-09.2010

  92. 92.

    Rozkalne A Hyman BT Spires-Jones TL Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model miceNeurobiol Dis2011 413650654

    Not in our library10.1016/j.nbd.2010.11.014

  93. 93.

    Spires-Jones TL Kay K Matsouka R Rozkalne A Betensky RA Hyman BT Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brainNeurosci Lett2011 4873260263

    Not in our library10.1016/j.neulet.2010.10.033

  94. 94.

    Zhang Y Kurup P Xu J Carty N Fernandez SM Nygaard HB Pittenger C Greengard P Strittmatter SM Nairn AC Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse modelProc Natl Acad Sci USA2010 107441901419019

    Not in our library10.1073/pnas.1013543107

  95. 95.

    Kurup P Zhang Y Venkitaramani DV Xu J Lombroso PJ The role of STEP in Alzheimer's diseaseChannels (Austin)2010 45347350

    Not in our library10.4161/chan.4.5.12910

  96. 96.

    Kurup P Zhang Y Xu J Venkitaramani DV Haroutunian V Greengard P Nairn AC Lombroso PJ Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61J Neurosci2010 301759485957

    Not in our library10.1523/jneurosci.0157-10.2010

  97. 97.

    Takasu MA Dalva MB Zigmond RE Greenberg ME Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptorsScience2002 2955554491495

    Not in our library10.1126/science.1065983

  98. 98.

    Henderson JT Georgiou J Jia Z Robertson J Elowe S Roder JC Pawson T The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic functionNeuron2001 32610411056

    Not in our library10.1016/s0896-6273(01)00553-0

  99. 99.

    Dalva MB Takasu MA Lin MZ Shamah SM Hu L Gale NW Greenberg ME EphB receptors interact with NMDA receptors and regulate excitatory synapse formationCell2000 1036945956

    Not in our library10.1016/s0092-8674(00)00197-5

  100. 100.

    Chen Y Fu AK Ip NY Bidirectional signaling of ErbB and Eph receptors at synapsesNeuron Glia Biol2008 43211221

    Not in our library10.1017/s1740925x09990287

  101. 101.

    Cisse M Halabisky B Harris J Devidze N Dubal DB Sun B Orr A Lotz G Kim DH Hamto P Reversing EphB2 depletion rescues cognitive functions in Alzheimer modelNature2011 46973284752

    Not in our library10.1038/nature09635

  102. 102.

    Simon AM de Maturana RL Ricobaraza A Escribano L Schiapparelli L Cuadrado-Tejedor M Perez-Mediavilla A Avila J Del Rio J Frechilla D Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's diseaseJ Alzheimers Dis2009 174773786

    Not in our library10.3233/jad-2009-1096

  103. 103.

    Vitolo OV Sant'Angelo A Costanzo V Battaglia F Arancio O Shelanski M Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signalingProc Natl Acad Sci USA2002 99201321713221

    Not in our library10.1073/pnas.172504199

  104. 104.

    Li S Jin M Koeglsperger T Shepardson NE Shankar GM Selkoe DJ Soluble A{beta} Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA ReceptorsJ Neurosci2011 311866276638

    Not in our library10.1523/jneurosci.0203-11.2011

  105. 105.

    Selkoe DJ Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behaviorBehav Brain Res2008 1921106113

    Not in our library10.1016/j.bbr.2008.02.016

  106. 106.

    Spires TL Meyer-Luehmann M Stern EA McLean PJ Skoch J Nguyen PT Bacskai BJ Hyman BT Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopyJ Neurosci2005 253172787287

    Not in our library10.1523/jneurosci.1879-05.2005

  107. 107.

    Rozkalne A Spires-Jones TL Stern EA Hyman BT A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse modelBrain Res2009 1280178185

    Not in our library10.1016/j.brainres.2009.05.045

  108. 108.

    Spires-Jones TL Mielke ML Rozkalne A Meyer-Luehmann M de Calignon A Bacskai BJ Schenk D Hyman BT Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer diseaseNeurobiol Dis2009 332213220

    Not in our library10.1016/j.nbd.2008.10.011

  109. 109.
    Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models · 1999
    Not checked
  110. 110.

    Kamenetz F Tomita T Hsieh H Seabrook G Borchelt D Iwatsubo T Sisodia S Malinow R APP processing and synaptic functionNeuron2003 376925937

    Not in our library10.1016/s0896-6273(03)00124-7

  111. 111.

    Ferrer I Gullotta F Down's syndrome and Alzheimer's disease: dendritic spine counts in the hippocampusActa Neuropathol1990 796680685

    Not in our library10.1007/bf00294247

  112. 112.

    Minamide LS Striegl AM Boyle JA Meberg PJ Bamburg JR Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite functionNat Cell Biol2000 29628636

    Not in our library10.1038/35023579

  113. 113.

    O'Hare E Weldon DT Mantyh PW Ghilardi JR Finke MP Kuskowski MA Maggio JE Shephard RA Cleary J Delayed behavioral effects following intrahippocampal injection of aggregated A beta (1-42)Brain Res1999 8151110

    Not in our library10.1016/s0006-8993(98)01002-6

  114. 114.

    Cleary JP Walsh DM Hofmeister JJ Shankar GM Kuskowski MA Selkoe DJ Ashe KH Natural oligomers of the amyloid-beta protein specifically disrupt cognitive functionNat Neurosci2005 817984

    Not in our library10.1038/nn1372

  115. 115.

    Cleary J Hittner JM Semotuk M Mantyh P O'Hare E Beta-amyloid(1-40) effects on behavior and memoryBrain Res1995 6821-26974

    Not in our library10.1016/0006-8993(95)00323-i

  116. 116.

    Kotilinek LA Bacskai B Westerman M Kawarabayashi T Younkin L Hyman BT Younkin S Ashe KH Reversible memory loss in a mouse transgenic model of Alzheimer's diseaseJ Neurosci2002 221563316335

    Not in our library10.1523/jneurosci.22-15-06331.2002

  117. 117.

    Dodart JC Bales KR Gannon KS Greene SJ DeMattos RB Mathis C DeLong CA Wu S Wu X Holtzman DM Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease modelNat Neurosci2002 55452457

    Not in our library10.1038/nn842

  118. 118.

    Klyubin I Walsh DM Lemere CA Cullen WK Shankar GM Betts V Spooner ET Jiang L Anwyl R Selkoe DJ Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivoNat Med2005 115556561

    Not in our library10.1038/nm1234

  119. 119.

    McLaurin J Kierstead ME Brown ME Hawkes CA Lambermon MH Phinney AL Darabie AA Cousins JE French JE Lan MF Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse modelNat Med2006 127801808

    Not in our library10.1038/nm1423

  120. 120.

    Gong Y Chang L Viola KL Lacor PN Lambert MP Finch CE Krafft GA Klein WL Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory lossProc Natl Acad Sci USA2003 100181041710422

    Not in our library10.1073/pnas.1834302100

  121. 121.

    Puzzo D Privitera L Fa M Staniszewski A Hashimoto G Aziz F Sakurai M Ribe EM Troy CM Mercken M Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memoryAnn Neurol2011 695819830

    Not in our library10.1002/ana.22313

  122. 122.

    Puzzo D Privitera L Leznik E Fa M Staniszewski A Palmeri A Arancio O Picomolar Amyloid-{beta} Positively Modulates Synaptic Plasticity and Memory in Hippocampus. 10.1523/JNEUROSCI.2692-08.2008J Neurosci2008 28531453714545

    Not in our library10.1523/jneurosci.2692-08.2008

  123. 123.

    Venkitaramani DV Chin J Netzer WJ Gouras GK Lesne S Malinow R Lombroso PJ Beta-amyloid modulation of synaptic transmission and plasticityJ Neurosci2007 27441183211837

    Not in our library10.1523/jneurosci.3478-07.2007

  124. 124.

    Abramov E Dolev I Fogel H Ciccotosto GD Ruff E Slutsky I Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapsesNat Neurosci2009 121215671576

    Not in our library10.1038/nn.2433

  125. 125.

    Micheva KD O'Rourke N Busse B Smith SJ Array tomography: production of arraysCold Spring Harb Protoc2010 201011pdb prot 5524

    Not in our library10.1101/pdb.prot5524

  126. 126.

    Micheva KD Smith SJ Array tomography: a new tool for imaging the molecular architecture and ultrastructure of neural circuitsNeuron2007 5512536

    Not in our library10.1016/j.neuron.2007.06.014

  127. 127.

    Lee EB Leng LZ Zhang B Kwong L Trojanowski JQ Abel T Lee VM Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic miceJ Biol Chem2006 281742924299

    Not in our library10.1074/jbc.m511018200

  128. 128.

    Cirrito JR Yamada KA Finn MB Sloviter RS Bales KR May PC Schoepp DD Paul SM Mennerick S Holtzman DM Synaptic activity regulates interstitial fluid amyloid-beta levels in vivoNeuron2005 486913922

    Not in our library10.1016/j.neuron.2005.10.028

  129. 129.

    Cirrito JR Kang JE Lee J Stewart FR Verges DK Silverio LM Bu G Mennerick S Holtzman DM Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivoNeuron2008 5814251

    Not in our library10.1016/j.neuron.2008.02.003

  130. 130.

    Cirrito JR May PC O'Dell MA Taylor JW Parsadanian M Cramer JW Audia JE Nissen JS Bales KR Paul SM In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-lifeJ Neurosci2003 232688448853

    Not in our library10.1523/jneurosci.23-26-08844.2003

  131. 131.

    Ting JT Kelley BG Lambert TJ Cook DG Sullivan JM Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanismsProc Natl Acad Sci USA2007 1041353358

    Not in our library10.1073/pnas.0608807104

  132. 132.

    Priller C Bauer T Mitteregger G Krebs B Kretzschmar HA Herms J Synapse formation and function is modulated by the amyloid precursor proteinJ Neurosci2006 262772127221

    Not in our library10.1523/jneurosci.1450-06.2006

  133. 133.

    Cerf E Gustot A Goormaghtigh E Ruysschaert JM Raussens V High ability of apolipoprotein E4 to stabilize amyloid-{beta} peptide oligomers, the pathological entities responsible for Alzheimer's diseaseFASEB J2011 25515851595

    Not in our library10.1096/fj.10-175976

  134. 134.

    Lauren J Gimbel DA Nygaard HB Gilbert JW Strittmatter SM Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomersNature2009 457723311281132

    Not in our library10.1038/nature07761

  135. 135.

    Barry AE Klyubin I Mc Donald JM Mably AJ Farrell MA Scott M Walsh DM Rowan MJ Alzheimer's Disease Brain-Derived Amyloid-{beta}-Mediated Inhibition of LTP In Vivo Is Prevented by Immunotargeting Cellular Prion ProteinJ Neurosci2011 312072597263

    Not in our library10.1523/jneurosci.6500-10.2011

  136. 136.

    Kessels HW Nguyen LN Nabavi S Malinow R The prion protein as a receptor for amyloid-betaNature2010 4667308E34; discussion E4-5

    Not in our library10.1038/nature09217

  137. 137.

    Balducci C Beeg M Stravalaci M Bastone A Sclip A Biasini E Tapella L Colombo L Manzoni C Borsello T Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion proteinProc Natl Acad Sci USA2010 107522952300

    Not in our library10.1073/pnas.0911829107

  138. 138.

    Calella AM Farinelli M Nuvolone M Mirante O Moos R Falsig J Mansuy IM Aguzzi A Prion protein and Abeta-related synaptic toxicity impairmentEMBO Mol Med2010 28306314

    Not in our library10.1002/emmm.201000082

  139. 139.

    Renner M Lacor PN Velasco PT Xu J Contractor A Klein WL Triller A Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5Neuron2010 665739754

    Not in our library10.1016/j.neuron.2010.04.029

  140. 140.

    Hyman BT Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer DiseaseArch Neurol2011

    Not in our library10.1001/archneurol.2011.70

  141. 141.

    Spires-Jones TL Kopeikina KJ Koffie RM de Calignon A Hyman BT Are Tangles as Toxic as They Look?J Mol Neurosci2011

    Not in our library10.1007/s12031-011-9566-7

  142. 142.

    Spires-Jones TL de Calignon A Meyer-Luehmann M Bacskai BJ Hyman BT Monitoring protein aggregation and toxicity in Alzheimer's disease mouse models using in vivo imagingMethods2011 533201207

    Not in our library10.1016/j.ymeth.2010.12.009

Cited by papers we hold 11

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.